image629
  • Home
  • Our Team
  • Clinical Need
  • Economic Benefit
  • Regulatory Status
  • Market Size
  • COVID-19
  • FAQ
  • FUSION DEVELOPMENT
  • AI In Medicine
  • Investor Relations
  • Careers
    • Home
    • Our Team
    • Clinical Need
    • Economic Benefit
    • Regulatory Status
    • Market Size
    • COVID-19
    • FAQ
    • FUSION DEVELOPMENT
    • AI In Medicine
    • Investor Relations
    • Careers
image630
  • Home
  • Our Team
  • Clinical Need
  • Economic Benefit
  • Regulatory Status
  • Market Size
  • COVID-19
  • FAQ
  • FUSION DEVELOPMENT
  • AI In Medicine
  • Investor Relations
  • Careers

COVID Statistics

image631

Worldwide Cases

As of the end of January, 2021 there have been over 100 million documented COVID-19 cases worldwide, with over 2 million deaths attributed to COVID-19

U.S. Cases

 As of the end of January, 2021 there have been over 26 million documented COVID-19 cases in the United States, with over 430,000 deaths attributed to COVID-19 

Find out more

U.S. Hospitalizations

Since the COVID-19 pandemic hit the U.S. in April 2020, there have been 30,000 to 120,000 COVID-19 patients hospitalized in the U.S. on a daily basis (see graph to the left)

Find out more

Mortality rate of hospitalized COVID-19 patients

In the U.S., the average mortality rate of patients admitted to the hospital with COVID related symptoms is around 15%

Find out more

Mortality rate of COVID-19 patients who require ICU care

Critically ill COVID-19 patients who require admission to the ICU for more advanced care, such as mechanical ventilation, have mortality rates of around 40%

Find out more

Risk factors for increased mortality from COVID-19 infection

Age greater than 75, obesity, and diabetes and hypertension are all risk factors for increased mortality from COVID-19

Find out more

Deleterious Affects of Elevated Glucose Levels in COVID

This graphic is from Zhu, Cell Metabolism, 2020

Animal study demonstrates increased lung injury from hyperglycemia

This animal study looked at the effect of elevated glucose levels on an animal model of acute lung injury. The animals with higher glucose levels sustained worse lung injury. The animals treated with insulin had less lung injury

Find out more

Lab study demonstrates increased COVID uptake/cytokine production when glucose levels are increased

A laboratory study demonstrated increased uptake of COVID viral particles into white blood cells (monocytes), with increasing glucose levels. This same study also demonstrated increased cytokine production by the COVID infected monocytes, when glucose levels were increased. The measured increase was at least 10X greater than what was measured with lower glucose levels

Find out more

LOWERING GLUCOSE LEVELS WITH IV INSULIN SIGNIFICANTLY LOWERS COVID MORTALITY RATES

An Italian study by Sardu demonstrated that when the blood glucose level was lowered through use of IV insulin, from the time of admission, that COVID mortality rates were significantly lowered. In this non-randomized study, patients admitted to the hospital with COVID were offered the choice of lowering their glucose levels with subcutaneous (SC) insulin injections or  IV insulin. The patients who chose SC insulin had average hospital glucose levels of 192 mg/dL, versus 138 mg/dL in the patients treated with IV insulin. The patients treated with IV insulin had significant lowering of their cytokine response, abnormalities on chest CT, and mortalIty rates

Find out more

Elevated glucose at admission and during hospitalization predicts increased mortality rates in COVID

A U.S. study by Bode on 570 COVID patients demonstrated that the group of patients (n= 184) with either diabetes or uncontrolled hyperglycemia (> 180 mg/dL) had a mortality rate of 28.8%, versus a mortality rate of 6.2% in the group of patients (n= 386) without diabetes or uncontrolled hyperglycemia. The average hospital glucose level of the diabetes/uncontrolled hyperglycemia group was 179 mg/dL, versus 117 mg/dL in the group without diabetes/uncontrolled hyperglycemia

Find out more

Elevated glucose during the first 48 hours of admission increases risk of death by 300% in COVID

A study by Matmani on 403 consecutively admitted COVID patients demonstrated that development of hyperglycemia during the first 48 hours of hospitalization increases the odds of dying by more than 300%. The group of patients who developed hyperglycemia had higher rates of ICU admission, development of severe pneumonia (ARDS), mechanical ventilation, and experienced a longer length of stay in the hospital. Overall, 57% of the patients in this study developed hyperglycemia 

Find out more

Hyperglycemia (> 140 mg/dl) in COVID patients admitted to the ICU almost doubles the mortality rate

A study by Saand on 495 COVID patients admitted to the ICU setting demonstrated that patients with an average glucose level greater than 140 mg/dL experience a mortality rate of 31.4 %, versus 16.6 % in patients whose average blood glucose was less than 140 mg/dL. Patients with hyperglycemia also had a 35% increase in the need for mechanical ventilation, and spent 2 more days in the ICU.

Find out more

Spanish study on over 11K COVID patients demonstrates admission glucose predicts mortality rate

This nationwide study from 109 hospitals in Spain demonstrated that the glucose level on admission was a good predictor of the patients mortality rate. The mortality rate was 15.7% when the admission glucose was less than 140 mg/dL, and increased to 41.1% when the admission glucose was greater than 180 mg/dL.

Find out more

China study on 7K COVID patients demonstrates elevated glucose associated with mortality rate

This Chinese study from 19 hospitals on 7,337 hospitalized COVID patients demonstrated that patients with type 2 diabetes had a 7.8% mortality rate versus 2.7% in those without type 2 diabetes. In a well matched subgroup of type 2 diabetes patients, they demonstrated that the group of patients (n = 250) with poorly controlled glucose levels (median glucose =191 mg/dL) had a mortality rate of 11.1%, versus 1.1% in the group (n =250) with well controlled  glucose levels (median glucose = 115 mg/dL). These differences in the matched type 2 diabetes subgroup occurred despite the two groups having similar chest CT findings on admission. The graphic seen to the left is from this study - Zhu, Cell Metabolism, 2020


Find out more

Meta-Analysis demonstrates admission hyperglycemia associated with COVID complications and mortality

A meta-analysis of 16 observational COVID studies of 6,386 patients demonstrated that the group of patients with elevated glucose levels on admission had increased risk of death (OR = 3.45) and severe complications (OR = 2.08)

Find out more

Dexcom G6 CGM in COVID

image632

Dexcom G6 CGM demonstrated to be 98% accurate when used in ICU setting on COVID patients

In this study performed on critically ill COVID patients, the majority of whom were receiving mechanical ventilation and/or vasopressor support, the Dexcom G6 CGM system had 98% of its values in the clinically relevant zones A & B on a Clarke error grid analysis. Glucose values in zones A and B  are considered to be accurate enough to be used for insulin treatment decisions, with no adverse clinical outcomes expected from use of glucose values in zones A & B

Find out more

Dexcom G6 CGM 100% accurate when used on COVID patients admitted to a non-ICU setting

In this small observational study, the Dexcom G6 CGM system was shown to have 100% of its values in zones A & B on a Clarke error grid analysis. The glucose mean absolute relative difference (MARD), which is a sensor error measurement, was less than 10% - this is an excellent result. In simulation studies of the FUSION systems AI based glucose control software, we achieved safe and effective glucose control when the glucose sensor error was set to 10%.

Find out more

Copyright © 2021 Ideal Medical Technologies - All Rights Reserved.

Powered by GoDaddy Website Builder